To investigate OM-specific immune responses shortly after the third vaccination (“post-3”; obtained prior to the OM wave), we analyzed a subset of 22 selected participants who had exhibited particularly strong spike protein-directed CD4+ responses in their pre-booster samples. The gene discussed is CD4; the disease is ocular melanoma.